9 hasil untuk "Stringhini, Marco"
Menampilkan 1–9 · 1,33 detik · RSS
-
Artikel Jurnal Teks lengkap
Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the sub-endothelial extracellular matrix
Antibody-drug conjugates (ADCs) represent a promising class of biopharmaceuticals with the potential to localize at the tumor site and improve the therapeutic index of cytotoxic drugs. While it is generally believed that ADCs need to be internalized into tumor cells in order to display optimal…
-
Artikel Jurnal Teks lengkap
Antibody-based delivery of TNF to the tumor neo-vasculature potentiates the therapeutic activity of a peptide anti-cancer vaccine
There is a growing interest in the use of tumor antigens for therapeutic vaccination strategies. Unfortunately, in most cases, the use of peptide vaccines in patients does not mediate shrinkage of solid tumor masses. Here, we studied the opportunity to boost peptide vaccination with F8-TNF, an…
-
Artikel Jurnal Teks lengkap
Antibody-mediated delivery of LIGHT to the tumor boosts natural killer cells and delays tumor progression
LIGHT is a member of the tumor necrosis factor superfamily, which has been claimed to mediate anti-tumor activity on the basis of cancer cures observed in immunocompetent mice bearing transgenic LIGHT-expressing tumors. The preclinical development of a LIGHT-based therapeutic has been hindered by…
-
Artikel Jurnal Teks lengkap
Antibody-based delivery of cytokine payloads to carbonic anhydrase IX leads to cancer cures in immunocompetent tumor-bearing mice
Antibody-cytokine fusion proteins can have the potential to increase the density and activity of subsets of leukocytes within the tumor mass. Here were describe the design, production and characterization of four novel antibody-cytokine fusion proteins directed against human carbonic anhydrase IX…
-
Artikel Jurnal Teks lengkap
A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo
The targeted delivery of interleukin-2 to the tumor is gaining attention as an avenue to potentiate the action of T and NK cells at the site of disease. We have previously described the fusion of the L19 antibody, specific to the EDB domain of fibronectin, with human interleukin-2, using a…
-
Artikel Jurnal Teks lengkap
An engineered 4-1BBL fusion protein with “activity on demand”
Engineered cytokines are gaining importance in cancer therapy, but these products are often limited by toxicity, especially at early time points after intravenous administration. 4-1BB is a member of the tumor necrosis factor receptor superfamily, which has been considered as a target for…
-
Artikel Jurnal Teks lengkap
Targeting an engineered cytokine with interleukin-2 and interleukin-15 activity to the neovasculature of solid tumors
There is a growing interest in the antibody-based delivery of cytokines to the tumor environment as a means to boost the anti-cancer activity of tumor-resident T cells and NK cells. Here, we describe the expression and characterization of fusion proteins, featuring the L19 antibody (specific to the…
-
Artikel Jurnal Teks lengkap
Cancer therapy in mice using a pure population of CD8(+) T cell specific to the AH1 tumor rejection antigen
There is a growing interest in the use of patient-derived T cells for the treatment of various types of malignancies. The expansion of a polyclonal and polyspecific population of tumor-reactive T cells, with a subsequent infusion into the same donor patient, has been implemented, sometimes with…
-
Artikel Jurnal Teks lengkap
A novel antibody-interleukin-15 fusion protein selectively localizes to tumors, synergizes with TNF-based immunocytokine and inhibits metastasis
Interleukin-15 (IL15) is an immunostimulatory cytokine which holds promises for cancer therapy, but its performance (alone or as partner for fusion proteins) has often been limited by suboptimal accumulation in the tumor and very rapid clearance from circulation. Most recently, the Sushi Domain…